American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6402)
  2. Solid Tumor Oncology Division (5540)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1638)
  6. Epidemiology and Biostatistics (1495)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1379)
  9. Gastrointestinal Oncology Service (1354)
  10. Hematologic Malignancies, Division of (1282)
Search Within
Formats
  1. Meeting Abstract (6344)
  2. Journal Article (2584)
  3. Editorial (76)
  4. Review (68)
  5. Guidelines (55)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6402)
  2. Solid Tumor Oncology Division (5540)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1638)
  6. Epidemiology and Biostatistics (1495)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (291)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8707)
  2. JCO Precision Oncology (171)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (10)

More Publications

Results (9183)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator's choice in patients with previously treated advanced cutaneous melanoma
    Meeting Abstract

    Luke, J. J.; Warner, A. B.; Chmielowski, B.; Diab, A.; Gebhardt, C.; Hernandez-Aya, L. F.; Hu-Lieskovan, S.; Karapetyan, L.; Lawrence, D. P.; McKean, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors resistant to anti-PD(L)-1
    Meeting Abstract

    Friedman, C. F.; Sullivan, R. J.; Tschernia, N.; Sonpavde, G. P.; Herrera, M.; He, K.; Bilusic, M.; Garralda, E.; Hernando-Calvo, A. H.; Silk, A. W.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase I study of AFNT-211, autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor in patients with advanced or metastatic solid tumors
    Meeting Abstract

    Basu, S. K.; Khan, B.; Payumo, F.; Wan, R.; Chiorean, E. G.; Gahvari, Z.; Hecht, J. R.; Hurwitz, M. E.; Leidner, R. S.; Lenz, H. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced solid tumors
    Meeting Abstract

    O'Cearbhaill, R. E.; Barve, M. A.; Darus, C.; Gabrail, N. Y.; Johannet, P.; Loh, J.; Lerose, M.; Andreas, K.; Ullmann, C. D.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • PRO-ACTIVE: Results of a pragmatic phase IV randomized trial comparing the effectiveness of prophylactic swallow intervention for patients receiving radiotherapy for head and neck cancer
    Meeting Abstract

    Hutcheson, K. A.; Fuller, C. D.; Pytynia, K. B.; Hope, A. J.; Ringash, J.; Thorpe, K.; Palma, D. A.; Theurer, J.; Mills, G.; Cracchiolo, J. R.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO-directed bispecific T-cell engager, in patients with advanced solid tumors
    Meeting Abstract

    D'Angelo, S. P.; Subbiah, V.; Blay, J. Y.; Wagner, M. J.; Steeghs, N.; Youk, J.; Mizusako, H.; Ohue, Y.; Jin, J.; Rajper, A. W.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Body mass index and somatic variants in biliary tract cancers
    Meeting Abstract

    Chou, J. F.; Capanu, M.; Srivastava, A.; Sigel, C. S.; Alsuwailem, R.; Berger, M. F.; Khalil, D. N.; Harding, J. J.; O'Reilly, E. M.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Overall survival with neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816
    Meeting Abstract

    Forde, P. M.; Spicer, J.; Provencio, M.; Mitsudomi, T.; Awad, M. M.; Wang, C. L.; Lu, S.; Felip, E.; Broderick, S.; Swanson, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+advanced solid tumors
    Meeting Abstract

    Sohal, D.; Iqbal, S.; Turcotte, S.; Botta, G. P.; Schlechter, B. L.; Ku, G. Y.; Hosein, P. J.; Saibil, S.; Gavriliuc, M.; Apostolopoulou, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer
    Meeting Abstract

    Cassier, P. A.; Van Laethem, J. L.; Borbath, I.; Macarulla, T.; Geboes, K. P.; Lambert, A.; Prenen, H.; Mitry, E.; Blanc, J. F.; Feliu, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save